ESR1 and neoplasm: Furthermore, tumours that did not exhibit a Ki67 response following preoperative endocrine therapy were enriched for genomic drivers of endocrine resistance, such as FGFR1 and CCND1 amplification, as well as intrachromosomal ESR1 fusions and enhanced E2F-mediated transcription [111,112].